Do It Yourself Stock Investor

2017 Stock Reviews

2017 summaries of buy-side stock analysis, sell/short, and general review. The equities covered trade in the NYSE, NASDAQ and OTC. Most analysis is hosted at Seeking Alpha, DIYSI's primary editor. Some reviews are native to this site.

Basic Stock Investing

by DIYSI
February 22, 2017

A basic question new, aspiring investors are too embarrassed to ask and financial blogs quickly skip over, "How do I buy stocks?" Most of the banking products offered will tie up money for five years and longer. A 5yr CD might return a measly 2% each year. A microcap and smallcap stock can return over 100% on investment in as little of time as one year. However, the investment comes with significant risk of loss compared to a conventional bank CD. Read the full DIY Stock Investor article.

Interview: Neptune Wellness Solutions CEO Jim Hamilton

by DIYSI
February 02, 2017

CEO Jim Hamilton took lead of the company in 2015 and has since steered them towards acquisitions and increased the variety of omega-3 products. Their growth chart is compelling and takes on a good turn-around story. The company recently received a $10m royalty agreement after completing settlements with a top competitor.

The name of the company has gone through transformations. The former name was Neptune Technologies & Bioressources Inc. (NASDAQ: NEPT) and remains on the SEC registration. They have since changed their name and branding to Neptune Wellness Solutions or even Neptune for short. Neptune is primarily a Business-to-Business (B2B) of Omega-3 Nutraceuticals. It once focused on a patented krill oil, but has since broadened via acquisitions to include many Omega-3 products. Read the full interview and listen to additional SoundCloud audio at Seeking Alpha.

Interview: Veru Healthcare CEO Dr. Mitchell Steiner

by DIYSI
January 09, 2017

During the early-80s Dr. Mitchell S. Steiner realized there was more to being a urologist. He chose a route in molecular biology, something of an emerging field back then. His studies began in the pre-Viagra era; most approaches were invasive and castration was common for prostate cancer.

Somewhere in the first fifteen minutes of the interview I was reminded that urology and the medical profession would lead to mentions most men steer away from: castration, STDs., sperm count, gonads, prophylactics... Yet, it was highly interesting like a visiting professor's colloquium. Read the full interview and listen to additional soundbites at Seeking Alpha.